BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/26/2024 7:56:28 AM | Browse: 97 | Download: 89
 |
Received |
|
2023-11-05 12:15 |
|
Peer-Review Started |
|
2023-11-05 12:16 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2023-12-06 00:02 |
|
Revised |
|
2023-12-19 18:35 |
|
Second Decision |
|
2024-01-15 02:45 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2024-01-15 04:55 |
|
Articles in Press |
|
2024-01-15 04:55 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-01-20 15:59 |
|
Publish the Manuscript Online |
|
2024-01-26 07:56 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Editorial |
| Article Title |
Revolutionizing gastric cancer treatment: The potential of immunotherapy
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Grigorios Christodoulidis, Konstantinos Eleftherios Koumarelas and Marina Nektaria Kouliou |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Grigorios Christodoulidis, MD, PhD, Surgeon, Department of General Surgery, University Hospital of Larissa, Mezourlo, Larissa 41110, Greece. gregsurg@yahoo.gr |
| Key Words |
Immunotherapy; Adaptive immunotherapy; Tumor vaccines; Chimeric antigen receptor therapy; Tumor-infiltrating lymphocytes therapy; Natural killer therapy; Cytokine-induced killer therapy; Engineered T cell receptor therapy; Immune checkpoint inhibitors |
| Core Tip |
Immunotherapy, especially immune checkpoint inhibitors (ICIs), has revolutionized cancer treatment by targeting programmed cell death 1, programmed cell death ligand 1 (PD-L1), and cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), enhancing the immune response. While PD-L1 and CTLA-4's prognostic significance in gastric cancer remains debatable, ICIs like nivolumab and pembrolizumab show promise. Tailored approaches, such as zolbetuximab for CLDN 18.2 or trastuzumab, pembrolizumab, and chemotherapy for human epidermal growth factor receptor 2-positive cases, demonstrate effectiveness. Tumor vaccines and dendritic cell-based vaccines hold potential in personalized therapy. Adoptive Immunotherapy utilizes tumor-infiltrating lymphocytes therapy, engineered T cell receptor therapy, Chimeric antigen receptor T-cell therapy, natural killer cell therapy, and cytokine-induced killer cell therapy, each with distinct benefits and challenges. The immunotherapy landscape continues to evolve, offering hope for improved cancer management. |
| Publish Date |
2024-01-26 07:56 |
| Citation |
Christodoulidis G, Koumarelas KE, Kouliou MN. Revolutionizing gastric cancer treatment: The potential of immunotherapy. World J Gastroenterol 2024; 30(4): 286-289 |
| URL |
https://www.wjgnet.com/1007-9327/full/v30/i4/286.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v30.i4.286 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
